Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease
Kazan medical journal · 15.06.2026 · 107 (3) · 479-480
DOI: 10.17816/kmj707876 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kazan medical journal, online erschienen am 15.06.2026.
Themen: Demenz
Abstract (Originalsprache)
This publication is the Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review: Nonino F, Minozzi S, Sambati L, Del Giovane C, Baldin E, Bassi MC, De Santis C, Gonzalez-Lorenzo M, Vignatelli L, Filippini G, Richard E. Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Cochrane Database of Systematic Reviews. 2026. Issue 4. Art. No.: CD016297. DOI: 10.1002/14651858.CD016297
Zitieren
APA
(2026). Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Kazan medical journal, 107(3), 479-480. https://doi.org/10.17816/kmj707876
Vancouver
Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Kazan medical journal. 2026;107(3):479-480. doi:10.17816/kmj707876
BibTeX
@article{euvimed2026,
title = {Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease},
journal = {Kazan medical journal},
year = {2026},
volume = {107},
number = {3},
pages = {479--480},
doi = {10.17816/kmj707876}
}
EUVIMED